On June 18, 2019, Shenzhen Beimei Pharmaceutical Co., Ltd. signed a license and cooperation agreement with Hetero, India. High-level officials from both sides celebrated the successful signing of the contract along the beautiful Huangpu River.

Beimei Pharmaceuticals has acquired the rights to the exclusive commercialization of four prescription medicines for children currently controlled by Hetero in China, all of which are first-line medicines in the treatment of related diseases.

Hetero India is the largest private pharmaceutical company in India, one of the leading generic pharmaceutical companies in India and the world's largest manufacturer of antiretroviral medicines, committed to the development, production and marketing of high-quality chemical and biological pharmaceuticals in a variety of therapeutic areas. Founded in 1993, Hetero has been one of the largest ARV API & FDF manufacturers in the world after 25 years of excellence, with a portfolio of more than 300 products, business networks in more than 126 countries and 21,000 employees worldwide. The company is renowned worldwide for its strengths in research and development, manufacturing and commercialization of a variety of products.

At present, Beimei Pharmaceutical Co., Ltd. has carried out product distribution in many fields such as respiratory system, anti-infection, nervous system, digestive system, endocrine system and so on according to the characteristics of high incidence of childhood diseases.

The partnership will further enrich the children's prescription medicine reserve products, believing that the product will have a broad market prospect after marketing, this successful introduction, through these four products, the sales of the company is expected to exceed 800 million.